Our Future Trials

The GI Cancer Institute has four trials in development, unlocking new treatments for people with GI cancer.



Using a robot rather than keyhole surgery could lead to a higher rate of successful surgeries for people with colon cancer. The RoLaCaRT-1 study, led by Professor Andrew Stevenson, will compare which treatment will deliver improvements in surgical, clinical and patient-reported outcomes.

“What we’re looking at is the number of times that patients will have successful surgery if it’s done robotically compared to laparoscopically,” says Professor Stevenson. “We suspect that there may be a 15-20% difference between those two groups.”



There is a large unmet need for people with metastatic colorectal cancer when standard therapy fails. Using a biopsy of the patient’s tumour tissue, new technology in the FORECAST-1 study models the effectiveness of anti-cancer treatments on individual cancers in a petri-dish, better tailoring each patient’s treatment.

Professor Peter Gibbs, the Study Chair of FORECAST-1, says, “What we’re hoping to do is to open up new treatment opportunities, along with increasing the precision of the treatments.”

Learn More



Pancreatic cancer is associated with a high prevalence of weight loss and malnutrition. Evidence suggests that changes in body composition can affect outcomes for patients at all stages of pancreatic cancer, but little is known about the best way to measure the loss of body composition or treat people who are affected by it.

RANDOMS is a substudy of the MASTERPLAN clinical trial for people with pancreatic cancer. Researchers aim to determine the best tool to measure nutrition and the loss of body composition for these patients.

Belinda Steer, Principal Investigator of the study, says, “This is an opportunity for us to collect valuable information on the nutritional status of pancreatic cancer patients.”